Colorectal Neoplasms Clinical Trial
— OPALOOfficial title:
A Phase II Trial to Evaluate the Efficacy and Safety of FOLFIRI + Panitumumab as First-line Treatment in Elderly Patients With RAS/BRAF Wild-type Unresectable Metastatic Colorectal Cancer and Good Performance Status
Verified date | June 2021 |
Source | Grupo Espanol Multidisciplinario del Cancer Digestivo |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
To estimate progression-free survival at one year in elderly patients with RAS/BRAF wild-type unresectable mCRC and good performance status treated with FOLFIRI + panitumumab as first-line therapy. The clinical hypothesis of this study is that the combination of panitumumab and FOLFIRI is a good treatment option in elderly patients with good performance status and RAS/BRAF wild-type unresectable mCRC. Another purpose of this clinical trial is to determine the RAS/BRAF mutation status in liquid biopsies at baseline and at the time of disease progression.
Status | Completed |
Enrollment | 20 |
Est. completion date | January 21, 2021 |
Est. primary completion date | January 21, 2021 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 70 Years and older |
Eligibility | Inclusion Criteria: 1. Males or females = 70 years, 2. Able to understand, sign and date an informed consent form approved by the IEC, 3. Histologically confirmed colorectal carcinoma with metastatic disease, 4. RAS/BRAF wild-type status in solid biopsy confirmed prior to inclusion of the study, 5. No previous treatment for metastatic disease, 6. Patients starting therapy with FOLFIRI + panitumumab with a treatment aim other than achieving potential resectability of the disease, 7. Independence in activities of daily living (ADL) based on the Katz Index and in instrumental activities of daily living (IAL) based on the Lawton Index, 8. Having no or only one comorbidity according to the Charlson Comorbidity Index. The following ones are not considered comorbidities as long as it is provided they are adequately controlled with medication: gastroduodenal ulcer, diabetes without target organs' damage, chronic respiratory disease and connective tissue disease. 9. Presence of at least one unidimensional measurable lesion = 10 mm according to RECIST criteria (version 1.1), 10. ECOG (Eastern Cooperative Oncology Group) performance status of 0-1, 11. Adequate bone marrow function: neutrophils = 1.5 x 10^9/l; platelets = 100 x 10^9/l; haemoglobin = 9 g/dl, 12. Hepatic, renal and metabolic function as follows: 1. Total bilirubin count = 1.5 x ULN; ALT and AST < 5 x ULN; 2. Renal function, calculated creatinine clearance or 24-hour creatinine clearance = 50 ml/min; 3. Magnesium > LLN Exclusion Criteria: 1. Diagnosed or suspected central nervous system (CNS) metastasis, 2. Patients with initially resectable metastases at the time of diagnosis of metastatic disease. 3. History or presence of another malignancy, with the exception of curatively treated in situ carcinoma of the cervix or non-melanoma skin cancer or any curatively treated solid tumour, with no active disease or administration of treatment within 5 years prior to inclusion in the study, 4. Prior treatment with irinotecan, 5. Prior adjuvant chemotherapy for colorectal cancer terminated less than 6 months before metastatic disease was diagnosed, 6. Prior anti-epidermal growth factor receptor (EGFR) antibody therapy (eg, cetuximab), anti- vascular endothelial growth factor (VEGF) or treatment with small molecule EGFR inhibitors (eg, erlotinib), 7. Unresolved toxicities from prior systemic treatment that, in the investigator's opinion, make the patient unsuitable for inclusion, 8. Hormone therapy, immunotherapy with experimental or approved antibodies/proteins (e.g. bevacizumab) = 30 days prior to inclusion, 9. Evidence of previous acute hypersensitivity reaction of any grade to any of the components of the treatment, 10. History of interstitial lung disease or pulmonary fibrosis or signs of interstitial lung disease or pulmonary fibrosis on baseline CT, 11. Presence of geriatric syndromes, defined as dementia, repeated falls, fecal incontinence or urinary incontinence, 12. Acute or subacute bowel obstruction and/or active bowel disease or another bowel disease causing chronic diarrhoea (defined as diarrhoea of grade = 2 according to the NCI (National Cancer Institute) Common Terminology Criteria for Adverse Events (CTCAE version 4.03), 13. Significant cardiovascular disease, including unstable angina pectoris or myocardial infarction within 12 months prior to inclusion in the study, 14. History of Gilbert's syndrome or dihydropyrimidine dehydrogenase deficiency, 15. Positive test result for human immunodeficiency virus, hepatitis C virus, chronic active hepatitis B infection, 16. Treatment for systemic infection within 14 days prior to the start of the study treatment, 17. Clinically significant sensory peripheral neuropathy, 18. Any concurrent disease that may increase the risk associated with study participation or may interfere with the interpretation of study results, 19. Any investigational product within 30 days prior to inclusion, 20. Surgery (not including diagnostic biopsy or the placement of a central line) and/or radiotherapy within 28 days prior to inclusion in the study, 21. Males whose partner is of child-bearing age and who does not agree to use adequate contraceptive precautions, i.e. double-barrier methods (e.g. diaphragm plus condom) or abstinence for the duration of the study and for 1 month after the last administration of the study drug, 22. Subjects who do not agree or are unable to meet the study requirements, 23. Psychological, familial, sociological or geographical conditions potentially hampering compliance with the study protocol and the follow-up schedule. Such conditions should be discussed with the patient before enrolment in the clinical trial |
Country | Name | City | State |
---|---|---|---|
Spain | Hospital Clínic | Barcelona | |
Spain | Hospital General Universitario de Elda | Elda | |
Spain | ICO L´Hospitalet de Llobregat - Hospital Durán i Reynals | L'Hospitalet de Llobregat | Barcelona |
Spain | Hospital Universitario Arnau de Vilanova | Lleida | |
Spain | Hospital Universitario la Paz | Madrid | |
Spain | Hospital Universitario Puerta de Hierro-Majadahonda | Majadahonda | Madrid |
Spain | Hospital Universitario Rey Juan Carlos | Móstoles | Madrid |
Spain | Hospital General Universitario Morales Meseguer | Murcia | |
Spain | Hospital Universitario Son Espases | Palma | |
Spain | Hospital Parc Taulí | Sabadell | |
Spain | Hospital Sant Joan Despí-Moises Broggi | Sant Joan Despí | Barcelona |
Spain | Hospital Clínico Universitario Lozano Blesa | Zaragoza |
Lead Sponsor | Collaborator |
---|---|
Grupo Espanol Multidisciplinario del Cancer Digestivo | Amgen, Pivotal S.L. |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | RAS/BRAF conversion proportion | Conversion rate of RAS/BRAF status at first-line treatment initiation and at the time of disease progression | At treatment initiation and at the time of PD (42 months) | |
Other | RAS/BRAF mutations' detection proportion | Detection rate of RAS/BRAF mutations in liquid biopsies at baseline in subjects with RAS/BRAF wild-type mCRC according to the solid biopsy analysis | At baseline | |
Primary | Progression-free survival at one year | Percentage of subjects still alive and progression free 12 months after inclusion in the study | 12 months after inclusion | |
Secondary | Progression-free survival (PFS) | Time (months) from inclusion in the trial until disease progression or death | 42 months | |
Secondary | Objective response rate | Proportion of patients with an objective response (complete or partial response) according to RECIST 1.1 criteria | 42 months | |
Secondary | Disease control rate | Proportion of patients with disease control (complete response, partial response or stable disease) | 42 months | |
Secondary | Duration of response | Time (months) from the first confirmation of objective response according to RECIST 1.1 criteria until disease progression or death | 42 months | |
Secondary | Time to response | Time (months) from inclusion in the trial until the date of the first confirmation of objective response according to RECIST 1.1 criteria | 18 months | |
Secondary | Overall survival (OS) | Time (months) from inclusion in the trial until death of the patient | 42 months | |
Secondary | Time to treatment failure | Time (months) from inclusion in the trial until progression, death or discontinuation due to toxicity | 18 months | |
Secondary | Proportion of patients with early tumour shrinkage (ETS) | Defined as tumour shrinkage = 30% at the first tumour assessment based on RECIST 1.1 criteria | 2 months | |
Secondary | Depth of response (DpR) | Measured as the maximum reduction ratio (percentage) of the tumour compared with baseline measurement (sum of diameters of the lesions) at the different assessments based on RECIST 1.1 criteria | 18 months | |
Secondary | Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] | Incidence and severity of adverse events. AEs description according to the NCI (National Cancer Institute) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 | 42 months | |
Secondary | Combined analysis of prognostic factors in metastatic disease | To analyse the number of lesions in liver and lung disease (1-3 vs 4-9 or =10), and the size of the largest lesion (<5 cm or = 5 cm), in correlation with the analytical values, mainly LDH and AP values. | 42 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04552093 -
Hepatic Arterial Infusion Pump Chemotherapy Combined With Systemic Chemotherapy (PUMP-IT)
|
Phase 2/Phase 3 | |
Completed |
NCT04192565 -
A Prospective Investigation of the ColubrisMX ELS System
|
N/A | |
Completed |
NCT05178745 -
A Prospective Observational Cohort Study Evaluating Resection Rate in Patients With Metastatic Colorectal Cancer Treated With Aflibercept in Combination With FOLFIRI - Observatoire résection
|
||
Recruiting |
NCT03561350 -
Detect Microsatellite Instability Status in Blood Sample of Advanced Colorectal Cancer Patients by Next-Generation Sequencing
|
||
Recruiting |
NCT06128798 -
Effect of Preoperative Immunonutrition Versus Standard Oral Nutrition in Patient Undergoing Colorectal Surgery.
|
N/A | |
Recruiting |
NCT03602677 -
Indocyanine Green Fluorescence Imaging in Prevention of Colorectal Anastomotic Leakage
|
N/A | |
Completed |
NCT03631407 -
Safety and Efficacy of Vicriviroc (MK-7690) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Microsatellite Stable (MSS) Colorectal Cancer (CRC) (MK-7690-046)
|
Phase 2 | |
Withdrawn |
NCT04192929 -
Chromoendoscopy or Narrow Band Imaging (NBI) for Improving Adenoma Detection in Colonoscopy
|
N/A | |
Recruiting |
NCT03042091 -
Neomycin and Metronidazole Hydrochloride With or Without Polyethylene Glycol in Reducing Infection in Patients Undergoing Elective Colorectal Surgery
|
Early Phase 1 | |
Completed |
NCT02889679 -
Underwater Resection of Non-pedunculated Colorectal Lesions
|
N/A | |
Terminated |
NCT02842580 -
De-escalation Chemotherapies Versus Escalation in Non Pre-treated Unresectable Patients With Metastatic Colorectal Cancer
|
Phase 2 | |
Completed |
NCT02564835 -
Effects of Yoga on Cognitive and Immune Function in Colorectal Cancer
|
N/A | |
Completed |
NCT02149108 -
Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1)
|
Phase 3 | |
Completed |
NCT02503696 -
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
|
N/A | |
Completed |
NCT02599103 -
The Effects of Various Cooking Oils on Health Related Biomarkers in Healthy Subjects
|
N/A | |
Completed |
NCT01719926 -
Phase I Platinum Based Chemotherapy Plus Indomethacin
|
Phase 1 | |
Completed |
NCT01669109 -
Hatha Yoga for Patients With Colorectal Cancer
|
N/A | |
Recruiting |
NCT01428752 -
Study of Prevalence of Colorectal Adenoma in 30- to 49-year-old Subjects With a Family History of Colorectal Cancer
|
N/A | |
Completed |
NCT01978717 -
General Anesthesia Combined With Epidural Anesthesia Mitigates the Surgical Stress-related Immunosuppression in Patients With Colorectal Cancer
|
N/A | |
Completed |
NCT01877018 -
Colorectal Cancer Screening in Primary Care
|
N/A |